// App-Quantinova.ai

2607 : TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors.

Researchers

Presenter

  • Desamparados Roda

Principal Investigators

  • Elena Geuna

  • Emma Hall

  • Timothy Anthony Yap

  • Susana N. Banerjee

  • Mary E.R. O'Brien

  • L Rhoda Molife

  • Stan B Kaye

  • Johann Sebastian De Bono

  • Bristi Basu

  • Angela Hayes

  • Karen E Swales

  • Sarah Jane Stimpson

  • Nitharsan Sathiyayogan

  • Nina Tunariu

  • Alison Joanne Turner

  • Udai Banerji

  • Saeed Rafii

  • Ruth Ruddle

Medical Centers

  • Cancer Research UK Cambridge Research Institute & Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United KingdomThe Institute of Cancer Research, London, United KingdomCambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • The Institute of Cancer Research, Sutton, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • The Royal Marsden Hospital, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Unspecified Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Paclitaxel

  • AZD-2014

Outcome

  • Unknown

Study Design

  • pharmacokinetics

  • pharmacodynamics

  • fixed dose

Phase

  • I

Study Id's

  • EudraCT number: 2012

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved